Frontiers in Endocrinology (Sep 2023)

Statins and risk of type 2 diabetes: mechanism and clinical implications

  • Markku Laakso,
  • Markku Laakso,
  • Lilian Fernandes Silva

DOI
https://doi.org/10.3389/fendo.2023.1239335
Journal volume & issue
Vol. 14

Abstract

Read online

Statins are widely used to prevent cardiovascular disease events. Cardiovascular diseases and type 2 diabetes are tightly connected since type 2 diabetes is a major risk factor for cardiovascular diseases. Additionally, cardiovascular diseases often precede the development of type 2 diabetes. These two diseases have common genetic and environmental antecedents. Statins are effective in the lowering of cardiovascular disease events. However, they have also important side effects, including an increased risk of type 2 diabetes. The first study reporting an association of statin treatment with the risk of type 2 diabetes was the WOSCOPS trial (West of Scotland Coronary Prevention Study) in 2001. Other primary and secondary cardiovascular disease prevention studies as well as population-based studies have confirmed original findings. The purpose of our review is to examine and summarize the most important findings of these studies as well as to describe the mechanisms how statins increase the risk of type 2 diabetes.

Keywords